Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today we highlight:
- a blog post suggesting a recent Supreme Court copyright-law decision is a “troubling signal for the branded pharmaceutical company trying to hold a generic manufacturer liable for induced patent infringement” in the skinny label case decided by the Federal Circuit;
- a blog post highlighting a recent Federal Circuit “decision regarding recombinant DNA subject-matter eligibility”; and
- a blog post discussing a recent Federal Circuit decision focusing on “whether . . . the patentee is entitled to damages reflecting foreign sales.”